pac2 Antibody

What is PAC-2 and what role does it play in proteasome assembly?

PAC-2 (Proteasome Assembly Chaperone 2, also known as PSMG2) functions as a critical chaperone protein that facilitates the assembly of the 20S proteasome. It forms a heterodimer with PSMG1 (PAC-1), and this complex plays several essential roles in proteasome biogenesis. Specifically, the PSMG1-PSMG2 heterodimer binds to the PSMA5 and PSMA7 proteasome subunits, promotes the assembly of proteasome alpha subunits into the heteroheptameric alpha ring structure, and prevents premature alpha ring dimerization . This chaperoning activity is crucial for the proper formation of functional proteasomes, which are essential for protein degradation and cellular homeostasis. Understanding PAC-2's function provides valuable insights into proteasome assembly mechanisms and potential implications for diseases related to proteasome dysfunction.

What are the alternative names and identifiers for PAC-2 protein?

PAC-2 is known by several alternative names and identifiers in the scientific literature and databases. These include PSMG2 (Proteasome Assembly Chaperone 2), HCCA3 (Hepatocellular Carcinoma-susceptibility protein 3), TNFSF5IP1 (Tumor Necrosis Factor Superfamily member 5-Induced Protein 1), and PAC2 . The diversity of nomenclature reflects the protein's discovery in different research contexts and its multiple biological roles. When searching literature databases or designing experiments, researchers should utilize these alternative identifiers to ensure comprehensive coverage of relevant research. This is particularly important when investigating PAC-2's various functional roles across different cellular processes and disease contexts.

What are the validated applications for PAC-2 antibodies in research?

Based on current research validation, PAC-2 antibodies have been thoroughly tested and confirmed effective for Western blot (WB) applications using human samples . Western blotting with PAC-2 antibodies typically reveals a predicted band size of approximately 29 kDa. The effectiveness of these antibodies has been validated across multiple human cell lines, including Caco-2 (intestinal epithelial cells), HepG2 (liver cancer cells), HeLa (cervical cancer cells), and Jurkat (T lymphocyte) cell lysates . For optimal results in Western blot applications, a recommended dilution ratio of 1/1000 has been established through empirical testing. While Western blotting represents the primary validated application, researchers should conduct preliminary tests when considering these antibodies for other immunological techniques such as immunohistochemistry, immunoprecipitation, or flow cytometry.

How should I optimize Western blot protocols for PAC-2 antibody detection?

Optimizing Western blot protocols for PAC-2 detection requires attention to several key methodological factors. Begin with sample preparation using an effective lysis buffer that preserves protein integrity while efficiently extracting PAC-2 (typically RIPA buffer supplemented with protease inhibitors). For gel electrophoresis, use 10-12% polyacrylamide gels, which provide optimal resolution for the 29 kDa PAC-2 protein . During transfer, nitrocellulose membranes typically yield better results than PVDF for this particular protein. For primary antibody incubation, a dilution ratio of 1/1000 has been experimentally validated as effective . Optimize blocking conditions (typically 5% non-fat milk or BSA in TBST) to minimize background while maintaining specific binding. Include appropriate positive controls (such as lysates from Caco-2, HepG2, HeLa, or Jurkat cells) that express detectable levels of PAC-2 . For troubleshooting purposes, if multiple bands appear, consider adjusting antibody concentration, increasing washing steps, or performing additional blocking to reduce non-specific binding.

What are the recommended cell lines and tissue types for studying PAC-2 expression?

For investigating PAC-2 expression patterns, several cellular models have been experimentally validated. Human cell lines with confirmed PAC-2 expression include Caco-2 (intestinal epithelial), HepG2 (hepatocellular carcinoma), HeLa (cervical cancer), and Jurkat (T-lymphocyte) cells . These represent diverse tissue origins and can be strategically selected based on research focus. When studying tissue-specific expression, liver tissue is particularly relevant given PAC-2's alternative name as Hepatocellular carcinoma-susceptibility protein 3 (HCCA3) . For comparative expression studies, researchers should consider analyzing PAC-2 levels across normal versus transformed cell states, or across developmental stages to elucidate temporal expression patterns. When preparing samples, optimize cell lysis protocols to ensure complete extraction of PAC-2, which may be differentially compartmentalized depending on cell type and physiological state. Quantitative analysis methods such as RT-qPCR can complement protein detection to provide a more comprehensive expression profile.

How can I verify the specificity of my PAC-2 antibody before experimental use?

Verifying antibody specificity is crucial for ensuring reliable experimental results. Implement a multi-step validation strategy beginning with positive and negative control samples. For positive controls, use lysates from cell lines with known PAC-2 expression such as Caco-2, HepG2, HeLa, or Jurkat cells . For negative controls, consider using lysates from cells where PAC-2 has been knocked down via siRNA or CRISPR-Cas9. Peptide competition assays provide another validation approach—pre-incubate the antibody with excess PAC-2-specific peptide before immunoblotting; specific binding should be significantly reduced. For recombinant monoclonal antibodies like [EPR9947(2)], check for documented specificity validation in published literature . Additionally, compare results using alternative antibody clones targeting different PAC-2 epitopes; concordant results across different antibodies increase confidence in specificity. Finally, molecular weight verification is essential—PAC-2 should appear at approximately 29 kDa , and significant deviations may indicate non-specific binding or post-translational modifications that warrant further investigation.

How does PAC-2 interact with other proteasome assembly chaperones in different cellular contexts?

PAC-2 functions within a complex network of proteasome assembly chaperones, with its primary partner being PSMG1 (PAC-1). The PSMG1-PSMG2 heterodimer specifically binds to the PSMA5 and PSMA7 proteasome subunits to facilitate proper assembly of the proteasome alpha subunits into the heteroheptameric alpha ring . This interaction network may vary across cellular contexts, particularly under stress conditions or in disease states. For investigating these interactions, co-immunoprecipitation using PAC-2 antibodies followed by mass spectrometry can identify novel binding partners. Proximity ligation assays can visualize in situ interactions between PAC-2 and other assembly factors. When designing such experiments, consider that cellular stressors (oxidative stress, heat shock, proteasome inhibition) may dynamically alter these interaction networks. Advanced microscopy techniques such as FRET or FLIM can measure interaction kinetics in living cells. Comparative analysis across different cell types (transformed versus primary cells) may reveal context-dependent interaction patterns that provide insights into tissue-specific proteasome assembly mechanisms and their potential dysregulation in disease.

What are the methodological approaches for studying PAC-2's role in proteasome assembly kinetics?

Investigating the kinetics of PAC-2's role in proteasome assembly requires specialized methodological approaches that capture temporal dynamics. Pulse-chase experiments with metabolic labeling can track the incorporation of newly synthesized PAC-2 into assembly intermediates. For real-time monitoring, develop fluorescently tagged PAC-2 constructs and employ live-cell imaging with fluorescence recovery after photobleaching (FRAP) to measure association/dissociation rates with proteasome components. Sucrose gradient fractionation combined with immunoblotting using PAC-2 antibodies can separate and identify assembly intermediates at different stages. To analyze the sequence of assembly events, synchronized cellular systems can be generated through proteasome inhibitor washout experiments, followed by time-course analysis of complex formation. For quantitative kinetic modeling, combine these approaches with mathematical models that incorporate rate constants derived from experimental data. When using antibody-based detection methods, ensure that epitope accessibility is not compromised in different assembly intermediates by comparing results with differently targeted PAC-2 antibodies.

How can I differentiate between PAC-2's direct effects and indirect consequences in proteasome assembly studies?

Distinguishing direct from indirect effects of PAC-2 in proteasome assembly requires carefully designed experimental approaches. Implement acute versus chronic PAC-2 depletion strategies—acute depletion (e.g., using auxin-inducible degron systems) primarily reveals direct functions, while chronic depletion (e.g., using CRISPR knockout) may trigger compensatory mechanisms and secondary effects. Structure-function analyses with PAC-2 mutants can identify specific domains required for direct interactions with proteasome subunits PSMA5 and PSMA7 . In vitro reconstitution assays using purified components provide a controlled system to observe direct biochemical activities without cellular complexity. Time-resolved studies are crucial—monitor the immediate consequences of PAC-2 manipulation before secondary effects emerge. For causal relationship testing, rescue experiments with wild-type PAC-2 after depletion can confirm direct functions. Proximity-dependent labeling methods (BioID, APEX) can map the immediate interaction network of PAC-2 in living cells. When using PAC-2 antibodies for such studies, verify that they do not interfere with the functional domains of PAC-2 that mediate its assembly chaperone activities.

What are common challenges when using PAC-2 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with PAC-2 antibodies. One common issue is non-specific binding, which manifests as multiple bands on Western blots beyond the expected 29 kDa band . This can be addressed by optimizing antibody concentration (try titrating from 1:500 to 1:2000), increasing blocking stringency (5-10% blocking agent), or extending wash steps. Background noise may be reduced by using freshly prepared buffers and high-quality blocking reagents. Another challenge is variable detection sensitivity across different sample types—if signal is weak in certain samples despite confirmed PAC-2 expression, consider using enhanced chemiluminescence substrates or signal amplification methods. Cross-reactivity with related proteins may occur, particularly with polyclonal antibodies; in such cases, switching to highly specific monoclonal antibodies like [EPR9947(2)] is recommended. For applications beyond Western blotting, epitope masking may occur; test multiple antibody clones targeting different regions of PAC-2 or optimize antigen retrieval methods. Batch-to-batch variability can be mitigated by purchasing larger lots and performing validation testing on each new lot against previously verified samples.

How should researchers interpret discrepant results between different PAC-2 antibodies?

Discrepancies between different PAC-2 antibodies require systematic investigation and careful interpretation. First, analyze the epitope locations—antibodies targeting different domains of PAC-2 may yield varying results if certain epitopes are masked in protein complexes or modified post-translationally. Compare antibody formats (polyclonal versus monoclonal, recombinant versus conventional) as these can significantly impact specificity and sensitivity profiles. For recombinant monoclonal antibodies like [EPR9947(2)] , consistency is typically higher than for polyclonal preparations. Evaluate documentation for each antibody, including validation data in specific applications and cell types. If discrepancies persist, perform orthogonal validation using non-antibody methods such as mass spectrometry or genetic approaches (siRNA, CRISPR) to confirm actual PAC-2 expression patterns. When contradictory results emerge regarding subcellular localization, consider fixation artifacts or epitope accessibility issues—compare multiple fixation protocols and permeabilization methods. For quantitative discrepancies, normalize data using housekeeping proteins and determine linear detection ranges for each antibody. Include biological controls (knockout/knockdown samples) to conclusively establish detection specificity for each antibody being compared.

What controls should be included when studying PAC-2 in complex experimental systems?

Robust experimental design for PAC-2 studies requires comprehensive controls. For antibody-based detection, include positive controls using cell lines with verified PAC-2 expression (Caco-2, HepG2, HeLa, Jurkat) alongside negative controls using PAC-2 knockout/knockdown samples. When studying PAC-2 in its heterodimeric form with PSMG1, simultaneous detection of both partners provides internal validation. For studying proteasome assembly, include controls for total proteasome content (e.g., using antibodies against constitutive proteasome subunits) to normalize assembly efficiency measurements. When manipulating PAC-2 levels, implement rescue controls by re-expressing PAC-2 in knockout systems to confirm phenotype specificity. For studying stress responses, include appropriate stress-only and unstressed controls. To control for post-translational modifications, use phosphatase or deubiquitinase treatments as needed. Technical controls should include isotype-matched irrelevant antibodies, secondary-only controls for immunofluorescence, and loading controls appropriate to the subcellular compartment being studied (not just housekeeping proteins). For quantitative studies, include standard curves using recombinant PAC-2 protein to ensure measurements fall within the linear range of detection.

What methodological approaches are recommended for studying PAC-2 in neurodegenerative disease models?

Investigating PAC-2 in neurodegenerative disease contexts requires specialized methodological considerations due to the critical importance of proteasome function in neuronal health. For tissue-based studies, optimize immunohistochemistry protocols using PAC-2 antibodies on brain sections, with particular attention to antigen retrieval methods as brain tissue often requires specialized processing. In cellular models, compare PAC-2 expression and localization across neuronal and glial cell types using immunofluorescence with neuron-specific markers. For disease-specific investigations, analyze PAC-2 levels and function in models expressing disease-associated proteins (e.g., mutant huntingtin, alpha-synuclein, tau). When using PAC-2 antibodies in brain tissue, validate specificity using knockout controls due to the complex nature of brain tissue and potential for cross-reactivity. To study the functional consequences of altered PAC-2 in neurons, measure proteasome assembly efficiency, activity, and clearance of disease-associated protein aggregates following PAC-2 manipulation. For in vivo studies, consider region-specific analyses, as proteasome composition and assembly may vary across brain regions. Temporal studies are particularly important in progressive neurodegenerative models to determine whether PAC-2 alterations precede or follow pathological changes.

How can antibody-based approaches be used to study PAC-2 interactions with the heteroheptameric alpha ring?

Advanced antibody-based techniques offer powerful tools for investigating PAC-2's interactions with proteasome components. Proximity ligation assays (PLA) can visualize and quantify in situ interactions between PAC-2 and specific alpha subunits (particularly PSMA5 and PSMA7) within intact cells. For temporal dynamics, combine PAC-2 antibodies with photoactivatable protein tags to track interaction kinetics during assembly processes. To dissect the structural basis of these interactions, epitope mapping with domain-specific PAC-2 antibodies can identify critical binding regions. For high-resolution studies, super-resolution microscopy (STORM, PALM) with PAC-2 antibodies can visualize assembly intermediates below the diffraction limit. To detect conformational changes during assembly, consider using conformation-specific antibodies that recognize PAC-2 only in certain structural states. Pull-down assays using PAC-2 antibodies followed by proteomic analysis can characterize the composition of assembly intermediates at different stages. When designing such experiments, ensure that antibody binding does not sterically hinder the interactions being studied. For validating key findings, complement antibody-based approaches with orthogonal methods such as crosslinking mass spectrometry or hydrogen-deuterium exchange.

What are the latest technological advancements in studying PAC-2 using computational antibody design?

Recent advances in computational antibody design offer new opportunities for studying PAC-2 biology. Modern biophysics-informed computational models can predict and design antibodies with customized specificity profiles for PAC-2 . These approaches involve identifying distinct binding modes associated with particular epitopes, allowing for the rational design of antibodies that can discriminate between very similar protein conformations or variants. When applied to PAC-2 research, such computational methods can generate antibodies specifically targeting distinct functional states (e.g., free PAC-2 versus PSMG1-bound PAC-2) or conformational transitions during proteasome assembly. Researchers can leverage databases like the Observed Antibody Space (OAS) , which contains over 1.5 billion cleaned, annotated antibody sequences, to inform antibody design for PAC-2 studies. For implementing these approaches, researchers should combine computational prediction with experimental validation using phage display or other selection methods. The integration of machine learning techniques with structural biology data can further enhance epitope prediction and antibody design specificity. These computational approaches are particularly valuable when traditional methods struggle to generate antibodies that can distinguish between closely related conformational states of PAC-2 during dynamic assembly processes.

How can researchers contribute their PAC-2 antibody validation data to improve community resources?

Contributing validation data for PAC-2 antibodies to community resources enhances research reproducibility and accelerates scientific progress. Researchers should consider submitting their antibody validation data to repositories like the Antibody Registry, Antibodypedia, or the Immune Epitope Database. When preparing submissions, include comprehensive validation across multiple applications (Western blot, immunoprecipitation, immunofluorescence) with appropriate positive and negative controls . Document the performance of PAC-2 antibodies across different experimental conditions, cell types, and tissue preparations. For enhanced rigor, include knockout/knockdown validation data demonstrating antibody specificity. Submission of raw blot images alongside processed results increases transparency and allows others to interpret findings independently. For computational approaches, contribute sequence data of validated PAC-2-specific antibodies to databases like the Observed Antibody Space (OAS) , which facilitates antibody design and comparison. When publishing research using PAC-2 antibodies, follow the Minimum Information About Antibody Validation reporting guidelines to ensure complete methodology description. Consider developing standard reference materials (e.g., recombinant PAC-2 protein standards) that can be shared with the research community to enable direct comparison of antibody performance across different laboratories.